Close Menu

NEW YORK – Fluidigm said on Tuesday that it has signed a distribution deal with De Novo Software to offer that firm's data-analysis tools alongside Fluidigm's mass cytometer platforms.

Under the agreement, new purchases of Fluidigm's Helios mass cytometer and Hyperion imaging system will include a one-year license for De Novo's FCS Express 7 Flow software for suspension data analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.